Javascript is not activated in your browser. This website needs javascript activated to work properly.
You are here

Antibody microarray-based oncoproteomics

  • Carl Borrebaeck
Publishing year: 2006
Language: English
Pages: 833-838
Publication/Series: Expert Opinion on Biological Therapy
Volume: 6
Issue: 8
Document type: Journal article
Publisher: Ashley Publications

Abstract english

The driving force behind oncoproteomics is the belief that certain protein signatures or patterns exist that are associated with a particular malignancy. if so, the correlation of clinical parameters with defined protein expression patterns would allow us to predict disease progression and perhaps even postulate improved therapeutic modalities. The technological challenges to achieve these goals are significant, as the human proteome is not defined. No general methodological approach exists today, and human cancer can, furthermore, be divided into several disease subgroups. One potential solution to finding cancer-associated protein signatures is the emerging technology of affinity proteomics. This approach addresses some of the shortcomings of traditional proteomics and combines it with the power of microarrays. The present review focuses on the role of antibody microarrays in oncoproteomics and its potential to provide a truly proteome-wide analytical approach.


  • Immunology in the medical area
  • recombinant
  • antibody
  • proteome analysis
  • microarray
  • affinity proteomics
  • cancer


  • ISSN: 1471-2598
Carl B
Carl Borrebaeck
E-mail: carl [dot] borrebaeck [at] immun [dot] lth [dot] se


Department of Immunotechnology




Create Health

+46 46 222 96 13